Class 514/44 - Polynucleotide (e.g., RNA, DNA, etc.)

Subclass of Class 514 - Drug, bio-affecting and body treating compositions
Definition: Subject matter which has the following structure, illustrated
No. of patents: 4416
Last issue date: 05/21/2013

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
8445454	Use on minicircle vectors for cardiac gene therapy Compositions and methods are provided for the treatment of an ischemic cardiovascular condition by providing a patient with a novel non-viral minicircle DNA vector comprising polynucleotide sequences that potentiate HIF-1 activity, including RNAi or antisense agents...	05/21/2013
8440635	Oligonucleotide conjugates Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an...	05/14/2013
8435960	Devices for improved wound management The present invention provides devices and compositions for the management of infection of topical lesions, each of the devices and compositions containing protonated/acidified nucleic acids either on its surface, or integrated into the device. These modified nuclei...	05/07/2013
8435961	Methods and compositions for increasing the activity of inhibitory RNA The invention provides methods for increasing the activity of an inhibitory RNA (RNAi) in a subject requiring administering one or more poly-ADP-ribose polymerase (PARP) inhibitors and/or one or more PARG activators to the subject. The invention also provides method...	05/07/2013
8431546	Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administr...	04/30/2013
8426375	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have ...	04/23/2013
8426377	iRNA agents with biocleavable tethers The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cle...	04/23/2013
8426374	Method for modifying myostatin expression A method comprising inhibiting myostatin expression or activity to increase muscle mass. Still further, methods for locally inhibiting myostatin expression or activity to reduce fibrosis are provided. The method comprises introducing a nucleotide sequence into a vec...	04/23/2013
8420618	MicroRNA-based method for anti-colorectal cancer effects and prognosis of colorectal cancer The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method o...	04/16/2013
8420616	MAT II beta subunit RNAi and therapeutic methods using same The presently disclosed subject matter generally relates to methods and compositions for modulating MAT II activity. More particularly, the presently disclosed subject matter relates to methods and compositions for inhibiting the expression of MAT II β subunit in a...	04/16/2013
8415320	Delivery of dsRNA to arthropods The invention is to methods of gene silencing in arthropods using dsRNA. The method is include contacting the arthropod with, and/or directly feeding the arthropod, the dsRNA to the arthropods to deliver the dsRNA to arthropod tissues. It is envisaged that the metho...	04/09/2013
8410071	Potent LNA oligonucleotides for the inhibition of HIF-1A expression The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastsc	04/02/2013
8410072	Use of a growth-stimulating protein This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or preventing or treating cancer growth, invasion or metastasis, or preventing...	04/02/2013
8410068	Compounds for the treatment or alleviation of edema, and methods for their use Isolated and substantially purified oligonucleotide compounds have been shown to be effective in reducing swelling and edema. Novel methods and substances are presented for the prevention, alleviation or treatment of edema of various aetiology. ...	04/02/2013
8404655	Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity The invention generally concerns inhibition of a molecule that has a role in post-translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ...	03/26/2013
8404654	Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound...	03/26/2013
8399423	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus. ...	03/19/2013
8399425	Alleviating neuropathic pain with EETs and sEH inhibitors The invention discloses methods of using cis-epoxyeicosantrienoic acids (“EETs”), inhibitors of soluble epoxide hydrolase (“sEH”), or a combination of an EET and an inhibitor of sEH, to alleviate neuropathic pain in subjects suffering from such pain. ...	03/19/2013
8399426	Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA The present invention relates to adenine nucleotide translocator 2 (ANT2) siRNA (small interfering RNA) or ANT2 shRNA (short hairpin RNA) suppressing the expression of ANT2 gene expression and anticancer agent containing the same. Furthermore, the present invention ...	03/19/2013
8394778	Regulators of NFAT and/or store-operated calcium entry Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involve...	03/12/2013
8394780	Targeting PAX2 for the treatment of breast cancer The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid ...	03/12/2013
8389489	Modulators of coagulation factors The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting co...	03/05/2013
8389493	Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach ...	03/05/2013
8383598	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have ...	02/26/2013
8383599	Methods and compositions for RNA interference The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least...	02/26/2013
8383601	Tissue specific gene therapy treatment The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca2+]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as...	02/26/2013
8377898	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have ...	02/19/2013
8372819	Methods and compositions for targeting skip Provided herein are methods and compositions for modulating apoptosis by targeting SKIP (Ski-interacting protein) activity. Methods of increasing DNA damage-induced cell death in cancer cells, and reducing DNA damage-induced cell death in normal cells are provided.	02/12/2013
8372785	Method for immobilizing self-organizing material or fine particle on substrate, and substrate manufactured by using such method A method for immobilizing a self-organizing material or fine particles on a substrate, and a substrate whereupon the self-organizing material or the fine particles are immobilized. More specifically, the method for immobilizing the fine particles including a nucleic...	02/12/2013
8372817	Small interfering RNA for gene knockdown of the subcutaneous N-methyl-D-aspartate receptor NR1 subunit, and it's application on pharmaceutics A small interfering RNA for gene knockdown of the N-methyl-D-aspartate receptor NR1 subunit comprises 21 to 25 ribonucleic acids, which are homologous to the RNA sequence of N-methyl-D-aspartate receptor NR1 subunit. A method of using the small interfering RNA, appl...	02/12/2013
8367633	Methods of treating B-cell cancers The present invention is directed to methods of causing malignant B-cells and treating malignant B-cells. These methods involve the use of an inhibitor of PKK activity, whether active directly against PKK or effective to knockdown PKK expression, which when introduc...	02/05/2013
8361982	Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a f...	01/29/2013
8361981	Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of ...	01/29/2013
8361976	Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules The present invention, at least in part, relates to the discovery of efficacious delivery of an RNAi agent (e.g., an siRNA) to a transplantable tissue. The agent may be used to minimize organ rejection, transplantation-mediated transmission of viral infection, and t...	01/29/2013
8361986	Synthetic agonists of TLR9 The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine...	01/29/2013
8357665	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have ...	01/22/2013
8357666	Reprogramming a cell by inducing a pluripotent gene through RNA interference The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method for inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodi...	01/22/2013
8357664	Antisense antiviral compound and method for treating influenza viral infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influe...	01/22/2013
8357670	Oligomeric compounds for the modulation of HIF-1A expression Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1...	01/22/2013
8354384	Anti-aging micrornas Methods and compositions for modulating aging genes or their targets for the treatment or prevention of senescence or symptoms thereof have been developed based on the discovery of naturally occurring inhibitory nucleic acids, in particular lin-4 miRNA, that downreg...	01/15/2013

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Quotables

PatentStorm News

Class 514/44 - Polynucleotide (e.g., RNA, DNA, etc.)